These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29531524)

  • 21. Structural Plasticity Induced by Ketamine in Human Dopaminergic Neurons as Mechanism Relevant for Treatment-Resistant Depression.
    Collo G; Cavalleri L; Merlo Pich E
    Chronic Stress (Thousand Oaks); 2019; 3():2470547019842545. PubMed ID: 32440593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BDNF interacts with endocannabinoids to regulate cocaine-induced synaptic plasticity in mouse midbrain dopamine neurons.
    Zhong P; Liu Y; Hu Y; Wang T; Zhao YP; Liu QS
    J Neurosci; 2015 Mar; 35(10):4469-81. PubMed ID: 25762688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ketamine increases the expression of GluR1 and GluR2 α-amino-3-hydroxy-5-methy-4-isoxazole propionate receptor subunits in human dopaminergic neurons differentiated from induced pluripotent stem cells.
    Collo G; Cavalleri L; Chiamulera C; Merlo Pich E
    Neuroreport; 2019 Feb; 30(3):207-212. PubMed ID: 30586092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Huperzine A Alleviates Oxidative Glutamate Toxicity in Hippocampal HT22 Cells via Activating BDNF/TrkB-Dependent PI3K/Akt/mTOR Signaling Pathway.
    Mao XY; Zhou HH; Li X; Liu ZQ
    Cell Mol Neurobiol; 2016 Aug; 36(6):915-925. PubMed ID: 26440805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons.
    Wang Y; Bouabid S; Darvas M; Zhou FM
    Exp Neurol; 2020 Nov; 333():113427. PubMed ID: 32735872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons.
    Du F; Li R; Huang Y; Li X; Le W
    Eur J Neurosci; 2005 Nov; 22(10):2422-30. PubMed ID: 16307585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.
    Imamura K; Takeshima T; Nakaso K; Ito S; Nakashima K
    Neurosci Lett; 2008 Aug; 440(2):97-102. PubMed ID: 18555604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
    Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. S 47445 counteracts the behavioral manifestations and hippocampal neuroplasticity changes in bulbectomized mice.
    Pilar-Cuellar F; Castro E; Bretin S; Mocaer E; Pazos Á; Díaz Á
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jul; 93():205-213. PubMed ID: 30980840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinson's Disease-Associated Changes in the Expression of Neurotrophic Factors and their Receptors upon Neuronal Differentiation of Human Induced Pluripotent Stem Cells.
    Novosadova EV; Nenasheva VV; Makarova IV; Dolotov OV; Inozemtseva LS; Arsenyeva EL; Chernyshenko SV; Sultanov RI; Illarioshkin SN; Grivennikov IA; Tarantul VZ
    J Mol Neurosci; 2020 Apr; 70(4):514-521. PubMed ID: 31820346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of mTOR dependent signaling pathway is a necessary mechanism of antidepressant-like activity of zinc.
    Szewczyk B; Pochwat B; Rafało A; Palucha-Poniewiera A; Domin H; Nowak G
    Neuropharmacology; 2015 Dec; 99():517-26. PubMed ID: 26297535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antidepressant-like effect of alarin is related to TrkB-mTOR signaling and synaptic plasticity.
    Zhuang F; Li M; Gao X; Wang Y; Wang D; Ma X; Ma T; Gu S
    Behav Brain Res; 2016 Oct; 313():158-171. PubMed ID: 27374162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transient and rapid activation of Akt/GSK-3β and mTORC1 signaling by D3 dopamine receptor stimulation in dorsal striatum and nucleus accumbens.
    Salles MJ; Hervé D; Rivet JM; Longueville S; Millan MJ; Girault JA; Mannoury la Cour C
    J Neurochem; 2013 May; 125(4):532-44. PubMed ID: 23410496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validated UHPLC-MS/MS method for the simultaneous determination of pramipexole and ropinirole in plasma of patients with Parkinson's disease.
    Mohamed S; Riva R; Contin M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Apr; 1017-1018():114-119. PubMed ID: 26970845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.
    Zagmutt FJ; Tarrants ML
    Int J Neurosci; 2012 Jul; 122(7):345-53. PubMed ID: 22304415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparable Neuroprotective Effects of Pergolide and Pramipexole on Ferrous Sulfate-Induced Dopaminergic Cell Death in Cell Culture.
    Reichelt D; Radad K; Moldzio R; Rausch WD; Reichmann H; Gille G
    CNS Neurol Disord Drug Targets; 2016; 15(10):1325-1332. PubMed ID: 27488420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
    Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
    Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.